Pivotal Phase 3 Study Results for Higher-Dose Quadrivalent Influenza Vaccine for Older Adults Published in The Lancet Infectious Diseases

CSL Seqirus announced the publication of pivotal Phase 3 study results for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases. This marks an important advance in influenza prevention for older adults, providing new evidence for healthcare professionals and policymakers considering future vaccination strategies. The trivalent formulation of aQIVc was previously approved by the MHRA in the UK for adults aged 50 and older.